Pesquisa | SciELO

Abstract To date, hydroxyurea is the only effective and safe drug that significantly reduces morbidity and mortality of individuals with Sickle cell disease. Twenty years of real-life experience has demonstrated that hydroxyurea reduces pain attacks, vaso-occlusive events, including acute chest syndrome, the number and duration of hospitalizations and the need for transfusion. The therapeutic success of hydroxyurea is directly linked to access to the drug, the dose used and adherence to treatment which, in part, is correlated to the availability of hydroxyurea. This consensus aims to reduce the number of mandatory exams needed to access the drug, prioritizing the requesting physician's report, without affecting patient safety. date disease reallife real life attacks vasoocclusive vaso occlusive events syndrome transfusion which part physicians physician s report safety

https://doi.org/10.1016/j.htct.2024.01.001

Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Bezerra, Matheus F.

; Larrazábal, Bruna R.

; Lima, Aleide S.

; Mello, Mariana R.

; Pimentel, Raphael F.

; Weinhäuser, Isabel

; Costa, Fernando F.

; Fertrin, Kleber Y.

; Araújo, Aderson S.

; Machado, Cíntia G.

; Bezerra, Marcos A.

; Lucena-Araujo, Antonio R.

Hematology, Transfusion and Cell Therapy

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Set 2022, Volume 44 Nº 3 Páginas 328 - 331

Resumo: En | Texto: En | PDF: En

ABSTRACT Introduction: One of the most critical complications in myelodysplastic syndromes (MDS) is the progression to acute myeloid leukemia (AML). The dynamics of clonal evolution in MDS and how acquired mutations can be used as biomarkers to track disease progression remains under investigation. Objective and method: Herein, we investigated the frequency of common myeloid clonal mutations (FLT3, NPM1, JAK2, IDH1 and IDH2) in 88 patients with MDS and 35 AML patients with myelodysplasia-related changes, followed at a single reference center in northeastern Brazil. Results: Overall, 9/88 (10%) ofthe MDSpatients and 9/35 (26%) of the secondary AML patients had at least one mutation. While the JAK2 V617F mutation was the most frequent in the MDS patients, the FLT3, NPM1, IDH1 and IDH2 mutations were more frequently found in the secondary AML group. Furthermore, there was a higher frequency of FLT3, NPM1, IDH1 and IDH2 mutations in MDS patients classified as high-risk subtypes than in those of lower risk. Conclusion: Despite the limited sample size, our data suggest that mutations in FLT3, NPM1, IDH1 and IDH2 genes could be potential biomarkers to detect early disease progression in MDS.

https://doi.org/10.1016/j.htct.2020.10.967

Association of HMIP1 C-893A polymorphism and disease severity in patients with sickle cell anemia
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Pereira-Martins, Diego A

; Domingos, Igor F

; Belini-Junior, Edis

; Coelho-Silva, Juan L

; Weinhäuser, Isabel

; Araújo, Aderson S

; Lobo, Clarisse L

; Bonini-Domingos, Claudia R

; Bezerra, Marcos A

; Lucena-Araujo, Antonio R

Hematology, Transfusion and Cell Therapy

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Set 2021, Volume 43 Nº 3 Páginas 243 - 248

Resumo: En | Texto: En | PDF: En

Abstract Introduction: Sickle cell anemia (SCA) is a Mendelian disorder with a heterogeneous clinical course. The reasons for this phenotypic diversity are not entirely established, but it is known that high fetal hemoglobin levels lead to a milder course of the disease. Additionally, genetic variants in the intergenic region HBS1L-MYB promote high levels of fetal hemoglobin into adulthood. Objective: In the present study, we investigated the HMIP1 C-839A (rs9376092) polymorphism, located at the HBS1L-MYB intergenic region block 1, in SCA patients. Method: We analyzed 299 SCA patients followed in two reference centers in Brazil. The HMIP1 C-839A (rs9376092) genotypes were determined by allele specific polymerase chain reactions. Clinical and laboratory data were obtained from patient interviews and medical records. Results: The median fetal hemoglobin levels were higher in patients with the HMIP1 C-839A (rs9376092) AA genotype (CC = 6.4%, CA = 5.6% and AA = 8.6%), but this difference did not reach significance (p = 0.194). No association between HMIP1 C-839A (rs9376092) genotypes and other clinical and laboratorial features was detected (p > 0.05). Conclusion: In summary, our data could not support the previously related association between the HMIP1 C-893A (rs9376092) polymorphism and differential fetal hemoglobin levels.

https://doi.org/10.1016/j.htct.2020.03.006 17 downloads

Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Cançado, Rodolfo D

; Araújo, Aderson da Silva

; Sandes, Alex Freire

; Arrais, Celso

; Lobo, Clarisse Lopes de Castro

; Figueiredo, Maria Stella

; Gualandro, Sandra Fátima Menosi

; Saad, Sara Teresinha Olalla

; Costa, Fernando Ferreira

Hematology, Transfusion and Cell Therapy

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Set 2021, Volume 43 Nº 3 Páginas 341 - 348

Resumo: En | Texto: En | PDF: En

Paroxysmal nocturnal hemoglobinuria is a chronic, multi-systemic, progressive and lifethreatening disease characterized by intravascular hemolysis, thrombotic events, serious infections and bone marrow failure. Paroxysmal nocturnal hemoglobinuria results from the expansion of a clone of hematopoietic cells that due to an inactivating mutation of the X-linked gene PIG-A are deficient in glycosylphosphatidylinositol-linked proteins. Early diagnosis, using flow cytometry performed on peripheral blood, the gold standard test to confirm the diagnosis of paroxysmal nocturnal hemoglobinuria, is essential for improved patient management and prognosis. The traditional therapy for paroxysmal nocturnal hemoglobinuria includes blood transfusion, anti-thrombosis prophylaxis or allogeneic bone marrow transplantation. The treatment that has recently become available is the complement blockade by the anti-C5 monoclonal antibody eculizumab. In this consensus, we are aiming to review the diagnosis and treatment of the paroxysmal nocturnal hemoglobinuria patients, as well as the early recognition of its systemic complications. These procedures express the opinions of experts and have been based on the best available evidence and international guidelines, with the purpose of increasing benefits and reducing harm to patients.

https://doi.org/10.1016/j.htct.2020.06.006 23 downloads

Polymorphisms in the heme oxygenase-1 and bone morphogenetic protein receptor type 1b genes and estimated glomerular filtration rate in Brazilian sickle cell anemia patients
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Chinedu, Okeke

; Tonassé, Wouitchékpo Vincent

; Albuquerque, Dulcinéia Martins

; Domingos, Igor de Farias

; Araújo, Aderson da Silva

; Bezerra, Marcos André Cavalcanti

; Sonati, Maria de Fátima

; Santos, Magnun Nueldo Nunes dos

Hematology, Transfusion and Cell Therapy

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Jun 2021, Volume 43 Nº 2 Páginas 165 - 170

Resumo: En | Texto: En | PDF: En

ABSTRACT Introduction Mutations affecting genes involved in oxidative and signaling pathways may be associated with kidney disease in sickle cell anemia. We determined the allele and genotype frequencies of some polymorphisms in the promoter regions of the Heme Oxygenase-1 (HMOX1) [rs2071746 (A > T) and (GT)n repeats, short (S) and long (L) alleles] and Bone Morphogenetic Protein Receptor type-1B (BMPR1B) [rs17022863 (A > G), rs4331783 (A > G) and rs1470409 (A > G)] genes in 75 adult patients with sickle cell anemia and 160 healthy controls and investigated whether these polymorphisms may influence the estimated glomerular filtration rate for the patients. Methods The single nucleotide polymorphisms were genotyped using the TaqMan assays, the HMOX1(GT)n repeats were determined by polymerase chain reaction fragment size analysis and the estimated glomerular filtration rate was calculated by the Modification of Diet in Renal Disease formula. Results Regarding the HMOX1rs2071746, the estimated glomerular filtration rate median was significantly higher in TT patients (p = 0.019), including when TT was compared with AT + AA (p = 0.009); for the (GT)n repeats, the estimated glomerular filtration rate medians of SS, SL and LL significantly differed (p = 0.009), being the LL estimated glomerular filtration rate median significantly higher, when compared with the LS + SS (p = 0.005). These results suggest that both the homozygotes, TT for rs2071746 and LL for (GT)n repeats, lead to a higher risk of developing renal complications. Concerning the BMPR1B, the frequencies of GG for rs17022863 and AA for rs4331783 were significantly higher in patients than in controls (p = 0.002 and p = 0.008, respectively), however no association with estimated glomerular filtration rate was found. Conclusion These results contribute to a better understanding of the genetic factors related to the development of nephropathy in sickle cell anemia patients.

https://doi.org/10.1016/j.htct.2020.01.009 82 downloads

Interleukin-6 in pregnancy with sickle cell disease
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Costa, Manuela Freire Hazin

; Torres, Leuridan Cavalcante

; Matta, Marina Cadena da

; Araújo, Aderson da Silva

; Souza, Ariani Impieri

Hematology, Transfusion and Cell Therapy

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Dez 2019, Volume 41 Nº 4 Páginas 298 - 302

Resumo: En | Texto: En | PDF: En

ABSTRACT Background: Despite advances in health care for sickle cell disease patients, as well as in the improvement in reproductive issues mainly in women with the disease, pregnancy is still a challenge, both for the mother and the child, with high rates of maternal and fetal morbidity and mortality. Besides their chronic hemolytic status and vaso-occlusive events that confer systemic complications, pregnant women also have higher rates of pain episodes, infections, abortion, intrauterine growth retardation, pre-term births, eclampsia, stillbirth and the hemolysis, elevated liver enzymes and low platelets syndrome. The physiologic mechanisms of the disease in pregnancy are still unknown and chronic inflammatory responses may interfere in the adverse outcomes. The cytokine and chemokine profiles in pregnancy with sickle cell disease remain unknown. The aim of this study was to evaluate the cytokine profile of the inflammatory response of pregnant women with sickle cell disease. Method: Blood samples from 20 pregnant women with sickle cell disease, 24 women with sickle cell disease in steady state, 16 healthy pregnant women and a control group with 9 women at childbearing age were assayed for interleukin-6. Main results: Pregnant women with sickle cell disease presented high serum levels of interleukin-6, compared to healthy pregnant women (p = 0.0115). Conclusion: These data suggest that the increased production of interleukin-6 may occur during pregnancy with sickle cell disease and that the role of this cytokine in the sickle cell disease pathophysiology and pregnancy complications should be further studied.

https://doi.org/10.1016/j.htct.2019.02.001 354 downloads

Combined genotypes of the MBL2 gene related to low mannose-binding lectin levels are associated with vaso-occlusive events in children with sickle cell anemia
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Medeiros, Fernanda Silva

; Mendonça, Taciana Furtado de

; Lopes, Katiuscia Araújo de Miranda

; França, Laís Medeiros da Câmara

; Silva, Andreia Soares da

; Vasconcelos, Luydson Richardson Silva

; Oliveira, Maria do Carmo Valgueiro Costa de

; Anjos, Ana Cláudia Mendonça dos

; Hatzlhofer, Betânia Lucena Domingues

; Bezerra, Marcos André Cavalcanti

; Araújo, Aderson da Silva

; Moura, Patrícia

; Cavalcanti, Maria do Socorro de Mendonça

Genetics and Molecular Biology

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Set 2017, Volume 40 Nº 3 Páginas 600 - 603

Resumo: En | Texto: En | PDF: En

Abstract Sickle cell anemia (SCA) presents heterogenous clinical manifestations that cannot be explained solely by alterations to hemoglobin (Hb); other components such as endothelial adhesion, thrombosis and inflammation may be involved. The mannose-binding lectin (MBL) has an important role in innate immunity and inflammatory diseases. In this report, we describe an association between MBL2 polymorphism related to low production of serum MBL and the frequency of vasoocclusive events (FVOE) in children ≤ 5 years old with SCA (p = 0.0229; OR 5.55; CI 1.11-27.66). Further studies are needed to explore the role of low MBL2 in the pathophysiology of vasoocclusive events in SCA.

https://doi.org/10.1590/1678-4685-gmb-2016-0161 792 downloads

Guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira – 2014
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Araújo, Aderson da Silva

; Lobo, Clarisse Lopes de Castro

; Covas, Dimas Tadeu

; Costa, Fernando Ferreira

; Medeiros, Letícia

; Cançado, Rodolfo Delfini

; Gualandro, Sandra Fátima Menosi

; Saad, Sara Teresinha Olalla

Revista Brasileira de Hematologia e Hemoterapia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Dez 2014, Volume 36 Nº 6 Páginas 450 - 453

Resumo: En | Texto: En | PDF: En

https://doi.org/10.1016/j.bjhh.2014.09.009 1896 downloads

Follow-up of children with hemoglobinopathies diagnosed by the Brazilian Neonatal Screening Program in the State of Pernambuco
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Soares, Ana Caroline Novaes

; Samico, Isabella Chagas

; Araújo, Aderson Silva

; Bezerra, Marcos André C.

; Hatzlhofer, Betânia Lucena Domingues

Revista Brasileira de Hematologia e Hemoterapia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Ago 2014, Volume 36 Nº 4 Páginas 250 - 255

Resumo: En | Texto: En | PDF: En

OBJECTIVE: To determine the geographical distribution of hemoglobinopathies in the State of Pernambuco, to characterize the children with these diseases and to describe factors associated with their follow-up at the referral center during the period from 2003 to 2010.METHODS: A retrospective, cross-sectional, descriptive study was carried out of 275 medical records from a total of 302 children with hemoglobinopathies diagnosed by the National Neonatal Screening Program in the State of Pernambuco in the study period. Microsoft Excel was used for data processing and analysis. The chi-square and the Fisher test were used for statistical analysis. The level of significance was set at 5%. Terra View software was used to analyze the geographical distribution of hemoglobinopathies in the State.RESULTS: A total of 8.9% of the cases of hemoglobinopathies detected in the period were not followed up at the referral center. For the mothers of children with diseases, this was their second or third or more pregnancy in 64.2% and 30.2%, respectively. Regarding the influence of region of residence and regular medical appointments, the study demonstrated that children from the Zona da Mata, Sertão and Vale do São Francisco regions did not attend 45.2%, 50% and 55.6% of their appointments in the outpatient department, respectively.CONCLUSIONS: This study shows that a significant number of children do not begin consultations in the outpatient clinic and even those who started treatment early and who have the most severe form of the disease, usually miss medical appointments.

https://doi.org/10.1016/j.bjhh.2014.05.001 1320 downloads

10.

Importância dos programas de triagem para o gene da hemoglobina S
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Bandeira, Flávia M. G. C.

; Bezerra, Marcos A. C.

; Santos, Magnun N. N.

; Gomes, Yara M.

; Araújo, Aderson S.

; Abath, Frederico G. C.

Revista Brasileira de Hematologia e Hemoterapia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Jun 2007, Volume 29 Nº 2 Páginas 179 - 184

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

A anemia falciforme caracteriza-se como quadro hemolítico hereditário que evolui cronicamente causando danos físicos e emocionais às pessoas acometidas. Até o presente momento não se dispõe de tratamento curativo, a não ser o transplante de medula óssea, que ainda tem sido realizado de maneira experimental. A triagem neonatal de hemoglobinopatias, principalmente da anemia falciforme, tem sido essencial ao diagnóstico precoce e à instituição de medidas preventivas e promotoras de saúde. No entanto, o Ministério da Saúde do Brasil recomenda o exame dos pais a partir da identificação de heterozigotos, mas não faz alusão quanto à ampliação da triagem para outros familiares. Uma família que possua uma criança afetada com estas síndromes passa a ter um marcador para um grupo genético de risco. Neste caso, a triagem ampliada para os familiares mais próximos (avós, pais, irmãos, tios e primos) poderá identificar muitos portadores ou casais em risco, antes do casamento e procriação, além de servir de base a programas de assessoramento genético e de controle epidemiológico das hemoglobinopatias, uma herança genética bastante freqüente em nossa população.

Sickle cell anemia is a hereditary condition that evolves to a chronic illness, causing physical and emotional disorders to those involved. As yet there is no cure except for bone marrow transplantation which is still in the experimental stage. Neonatal screening for hemoglobin disorders, particularly sickle cell anemia, has been crucial for ensuring early diagnosis and the application of preventive and health-promoting measures. The Brazilian Health Ministry recommends testing parents thereby identifying heterozygotes, but does not propose extending this screening to other family members. A family that has a child affected by one of these syndromes is a marker for an at-risk group. In this case extending screning to close relatives (grandparents, siblings, aunts and uncles, and cousins) may identify individuals affected by the disease or couples at risk before marriage and reproduction and serve as the basis for programs providing genetic evaluation and epidemiological control of hemoglobin diseases that are relatively common in the Brazilian population.

8702 downloads

11.

Hidroxiuréia em pacientes com síndromes falciformes acompanhados no Hospital Hemope, Recife, Brasil
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Bandeira, Flavia M. G. C.

; Peres, Jaqueline C.

; Carvalho, Eduardo J.

; Bezerra, Ivane

; Araújo, Aderson S.

; Mello, Mariana R. B.

; Machado, Cíntia

Revista Brasileira de Hematologia e Hemoterapia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

2004, Volume 26 Nº 3 Páginas 189 - 194

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

O uso de hidroxiuréia promove a elevação dos níveis de hemoglobina fetal (Hb F) em pacientes portadores de síndromes falciformes (SF) e o medicamento vem sendo estudado em vários grupos de pacientes, incluindo adultos e crianças. O presente trabalho analisou a eficácia e tolerabilidade do uso de hidroxiuréia em crianças na faixa etária entre 5 e 17 anos de idade e em adultos jovens acima de 18 anos, portadores de hemoglobinopatia SS ou Sbeta0 que foram acompanhados regularmente no ambulatório do Hospital Hemope. Os pacientes pediátricos foram tratados com dose inicial de hidroxiuréia de 10 mg/kg/dia, a qual era aumentada em 5 mg/kg por dia em intervalos de oito semanas, até a dose máxima de 25 mg/kg/dia. Para os adultos, o tratamento foi iniciado com 500 mg/dia de hidroxiuréia até a dose máxima de 1g/dia. Foi observada redução do número de crises álgicas assim como do número de internações hospitalares, elevação do nível de Hb F e do Volume Corpuscular Médio, no grupo pediátrico. Entre os pacientes maiores de 18 anos, também se observou melhora clínica e significância estatística com aumento dos valores da hemoglobina e redução dos valores de reticulócitos, leucócitos e plaquetas. Não foram observados sinais ou sintomas sugestivos de toxicidade medicamentosa em ambos os grupos. O uso de hidroxiuréia em todos os pacientes parece ser seguro e eficaz e assegura melhora da qualidade de vida e benefícios a seus familiares. Ademais, as doses preconizadas de hidroxiuréia aparentemente não foram mielotóxicas, não tendo sido necessária a suspensão do tratamento em nenhum dos pacientes.

The use of hydroxyurea increases concentrations of fetal hemoglobin (Hb F) in sickle cell disease patients. It has been used in adults and in trials with children with the aim of preventing events such as episodes of pain or stokes. The objective of this study was to analyze the efficacy and side effects of Hydroxyurea in children with ages ranging from 5 to 17 years and also in young adults with SS or Sbeta0 hemoglobinopathies. The patients were treated in the outpatient clinic of the Hemope Hospital. Young patients were treated with hydroxyurea at 10 mg/kg/day which was increased by 5 mg/kg/day at 8-week intervals until reaching a maximum dose of 25 mg/kg/day. For adults, the treatment started at 500 mg/day and increased until a dose of 1000 mg/day was reached. Total Hb F levels and the Mean Corpuscular Volume rose with hydroxyurea therapy and there was a reduction of events involving pain as well as the necessity of hospitalization among the pediatric patients. With the over 18-year-old patients, a better clinical state was noticed together with a rise in hemoglobin levels and a reduction in the reticulocyte, leukocyte and platelet counts. No signs or symptoms in respect to drug toxicity were evidenced in either group. The use of hydroxyurea seems to be safe and effective in both children and young adults with sickle cell disease. The drug also improves the quality of life of these patients and their families. Additionally, the dosages of hydroxyurea used in this group of patients did not cause any bone marrow toxicity or other side effects.

25980 downloads

Exibindo

itens por página

Página de 1 Próxima

Selecione um ou mais resultados

Todos Ordem alfabética

Resultados

Gráfico comparativo Download CSV

Visualizar estatísticas de

Enviar resultado

E-mail do(s) destinatários*

Utilize ; (ponto e vírgula) para mais de um e-mail.

Enviar por e-mail

Esta página

Registros selecionados

Todos os registros (max. 300)

Alterar remetente, assunto e comentários

Seu email

Assunto

Comentários

Alterar remetente, assunto e comentários

Exportar resultados

Formato de exportação:

RIS (para EndNote, ProCite, Reference Manager, RefWorks, Citavi, etc.)

BibTeX

Citação

CSV (para Excel, etc)

Exportar:

Esta página

Itens selecionados

Todos os registros (max. 2000)

Mostrar mais

Sem resultados

Não foram encontrados documentos para sua pesquisa

Glossário e ajuda para busca

Você pode enriquecer sua busca de uma forma muito simples. Use os índices de pesquisa combinados com os conectores (AND ou OR) e especifique cada vez mais sua busca.

Por exemplo, se você deseja buscar artigos sobre
casos de dengue no Brasil em 2015, use:
ti:dengue and publication_year:2015 and aff_country:Brasil

Veja abaixo a lista completa de índices de pesquisa que podem ser usados:

Cód. do Índice	Elemento
ti	título do artigo
au	autor
kw	palavras-chave do artigo
subject	assunto (palavras do título, resumo e palavras-chave)
ab	resumo
ta	título abreviado da revista (ex. Cad. Saúde Pública)
journal_title	título completo da revista (ex. Cadernos de Saúde Pública)
la	código do idioma da publicação (ex. pt - Português, es - Espanhol)
type	tipo do documento
pid	identificador da publicação
publication_year	ano de publicação do artigo
sponsor	financiador
aff_country	código do país de afiliação do autor
aff_institution	instituição de afiliação do autor
volume	volume do artigo
issue	número do artigo
elocation	elocation
doi	número DOI
issn	ISSN da revista
in	código da coleção SciELO (ex. scl - Brasil, col - Colômbia)
use_license	código da licença de uso do artigo

SciELO - Scientific Electronic Library Online
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil
Email: scielo@scielo.org

Todo o conteúdo de www.scielo.org, exceto onde está identificado, está licenciado sob uma Licença Creative Commons.
saiba mais »